Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Talquetamab, First-in-Class Bispecific Monoclonal Antibody, Granted Breakthrough Therapy by the FDA for Relapsed or Refractory Multiple Myeloma

JHOP - August 2022 Vol 12, No 4 - FDA Oncology Update
NEW BREAKTHROUGH THERAPY

On June 29, 2022, the FDA granted the investigational first-in-class anti-CD3 and anti-GPRC5D bispecific humanized monoclonal antibody talquetamab (Janssen) a breakthrough therapy designation for relapsed or refractory multiple myeloma in patients who have received ≥4 previous lines of therapy, including a proteosome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. In May 2021, the FDA granted talquetamab an orphan drug designation for the treatment of multiple myeloma.

“This breakthrough therapy designation marks an important step in the continued development of talquetamab, a first-in-class bispecific antibody T-cell engager using GPRC5D,” said Sen Zhuang, MD, PhD, Vice President, Clinical Research and Development, Janssen Research and Development, in a press release. “Despite the therapies available for patients with relapsed or refractory multiple myeloma, new targets and treatments are needed because of the heterogeneity of the disease, which can impact a patient’s response to treatment.”

This approval was based on the results of the phase 1/2 MonumenTAL-1 study, a first-in-human dose-escalation clinical trial that enrolled heavily pretreated patients with relapsed or refractory multiple myeloma. Talquetamab is currently being evaluated for the treatment of relapsed or refractory multiple myeloma, as well as in combination with the investigational T-cell redirecting bispecific antibody targeting B-cell maturation antigen teclistamab, for the treatment of relapsed or refractory multiple myeloma.

Related Items
Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pedmark First Drug Approved for Hearing Loss Prevention in Children with Solid Tumors
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.